首次诊断为乳腺癌的患者中约5%~10%为局部进展期乳腺癌。目前越来越多的患者接受术前新辅助化疗。虽然行新辅助化疗患者的无瘤生存、总生存率、肿瘤局部控制率与传统的手术加术后辅助化疗相似,但其能够缩小肿瘤,可使更多患者接受保乳手术。组织病理学反应可作为评价新辅助化疗 About 5% to 10% of patients diagnosed with breast cancer for the first time are locally advanced breast cancer. Currently, more and more patients receive preoperative neoadjuvant chemotherapy. Although neoadjuvant chemotherapy in patients with tumor-free survival, overall survival and local tumor control rate with traditional surgery plus adjuvant chemotherapy is similar, but it can reduce the tumor, allowing more patients undergoing breast-conserving surgery. Histopathological responses can be evaluated as neoadjuvant chemotherapy